



## NeuroVista Completes Convertible Debt Agreement and Second Technology License with Cyberonics

**Seattle, WA—August 18, 2010**—NeuroVista Corporation, a developer of innovative medical technologies for the management and treatment of epilepsy, today announced it has completed a \$5 million convertible debt agreement with Cyberonics, Inc. In addition, NeuroVista has entered into a second License Agreement with Cyberonics, following up on a successful initial License Agreement between the two companies in October 2009. The second License Agreement provides Cyberonics with additional technology related to recharging systems for implantable devices.

“We are excited about the opportunity to broaden our relationship with a pioneer and leader in the field of epilepsy, and to assist Cyberonics in its continued innovation for the VNS Therapy System,” said John F. Harris, President and Chief Executive Officer of NeuroVista.

“The NeuroVista and Cyberonics teams have had very productive and harmonious collaborations over the past year,” said Dan Moore, President and Chief Executive Officer of Cyberonics. “We will continue to explore opportunities for creating value as NeuroVista pursues its clinical studies of the NeuroVista<sup>®</sup> Seizure Advisory System<sup>™</sup>.”

### **About Cyberonics, Inc. and VNS Therapy<sup>®</sup>**

Cyberonics, Inc. (NASDAQ: CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide. Additional information on Cyberonics and VNS Therapy is available at [www.cyberonics.com](http://www.cyberonics.com).

### **About NeuroVista**

NeuroVista is clinical stage medical device company pioneering new technologies that will revolutionize the management and treatment of epilepsy. Epilepsy is a neurological condition affecting approximately 1% of the U.S. population—more than Parkinson’s disease, multiple sclerosis, and Lou Gehrig’s disease combined. NeuroVista is a privately held company based in Seattle. For more information visit [www.neurovista.com](http://www.neurovista.com).